利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

31 条记录 (耗时 0.041 秒)

    Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
    1.
    发明申请
    Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling 有权
    基于基因表达谱的多发性骨髓瘤的潜在治疗靶点的诊断，预后和鉴定

    公开(公告)号：US20050282192A1

    公开(公告)日：2005-12-22

    申请号：US11110209

    申请日：2005-04-20

    申请人： John Shaughnessy ,  Bart Barlogie ,  Fenghuang Zhan

    发明人： John Shaughnessy ,  Bart Barlogie ,  Fenghuang Zhan

    IPC分类号： C12Q1/68 ,  G06F19/00

    CPC分类号： C12Q1/6886 ,  C12Q1/6809 ,  C12Q1/6837 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  Y02A90/26 ,  C12Q2565/501

    摘要： Gene expression profiling is a powerful tool that has varied utility. It enables classification of multiple myeloma into subtypes and identifing genes directly involved in disease pathogensis and clinical manifestation. The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myleoma. It is further contemplated that therapeutic strategies that directly target CKS1B or related pathways may represent novel, and more specific means of treating high risk myeloma and may prevent its secondary evolution.

    摘要翻译： 基因表达谱是一种功能多样的强大工具。 它可以将多发性骨髓瘤分类为亚型，并确定直接参与疾病病理和临床表现的基因。 本发明在大量均匀治疗的骨髓瘤患者群中使用基因表达谱来鉴定与预后不良相关的基因。 它还表明CKS1B基因的过表达，主要是由于通过荧光原位杂交确定的基因扩增，以在多种myleoma中预后不良。 进一步预期，直接靶向CKS1B或相关途径的治疗策略可以代表治疗高风险骨髓瘤的新颖和更具体的手段，并且可以防止其二次进化。

    Use of gene expression profiling to predict survival in cancer patient
    2.
    发明申请
    Use of gene expression profiling to predict survival in cancer patient 有权
    使用基因表达谱来预测癌症患者的存活

    公开(公告)号：US20050260664A1

    公开(公告)日：2005-11-24

    申请号：US11133937

    申请日：2005-05-20

    申请人： John Shaughnessy ,  Fenghuang Zhan ,  Bart Barlogie

    发明人： John Shaughnessy ,  Fenghuang Zhan ,  Bart Barlogie

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158

    摘要： Gene expression profiling in multiple myeloma patients identifies genes that distinguish between patients with subsequent early death or long survival after treatment. Poor survival is linked to over-expression of genes such as ASPM, OPN3 and CKS1B which are located in chromosome 1q. Given the frequent amplification of 1q in many cancers, it is possible that these genes can be used as powerful prognostic markers and therapeutic targets for multiple myeloma and other cancer.

    摘要翻译： 在多发性骨髓瘤患者中进行基因表达谱分析鉴定了随后早期死亡或治疗后长期存活的患者之间区分的基因。 差的存活与位于染色体1q的基因如ASPM，OPN3和CKS1B的过表达有关。 鉴于许多癌症中1q的频繁扩增，这些基因可能被用作多种骨髓瘤和其他癌症的强大的预后标志物和治疗靶点。

    Use of gene expression profiling to predict survival in cancer patient
    3.
    发明申请
    Use of gene expression profiling to predict survival in cancer patient 有权
    使用基因表达谱来预测癌症患者的存活

    公开(公告)号：US20060003365A1

    公开(公告)日：2006-01-05

    申请号：US11147829

    申请日：2005-06-08

    申请人： John Shaughnessy ,  Bart Barlogie ,  Fenghuang Zhan

    发明人： John Shaughnessy ,  Bart Barlogie ,  Fenghuang Zhan

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/178

    摘要： Gene expression profiling in multiple myeloma patients identifies genes that distinguish between patients with subsequent early death or long survival after treatment. Poor survival is linked to over-expression of genes such as ASPM, OPN3 and CKS1B which are located in chromosome 1q. Given the frequent amplification of 1q in many cancers, it is possible that these genes can be used as powerful prognostic markers and therapeutic targets for multiple myeloma and other cancer.

    摘要翻译： 在多发性骨髓瘤患者中进行基因表达谱分析鉴定了随后早期死亡或治疗后长期存活的患者之间区分的基因。 差的存活与位于染色体1q的基因如ASPM，OPN3和CKS1B的过表达有关。 鉴于许多癌症中1q的频繁扩增，这些基因可能被用作多种骨髓瘤和其他癌症的强大的预后标志物和治疗靶点。

    Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
    4.
    发明申请
    Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling 失效
    基于基因表达谱的多发性骨髓瘤的潜在治疗靶点的诊断，预后和鉴定

    公开(公告)号：US20050112630A1

    公开(公告)日：2005-05-26

    申请号：US10931780

    申请日：2004-09-01

    申请人： John Shaughnessy ,  Bart Barlogie ,  Fenghuang Zhan

    发明人： John Shaughnessy ,  Bart Barlogie ,  Fenghuang Zhan

    IPC分类号： C12Q1/68 ,  G01N33/48 ,  G01N33/50 ,  G06F19/00

    CPC分类号： C12Q1/6886 ,  C12Q1/6837 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  Y02A90/26

    摘要： Gene expression profiling reveals four distinct subgroups of multiple myeloma that have significant correlation with various clinical characteristics. Diagnosis for multiple myeloma (and possibly monoclonal gammopathy of undetermined significance) based on differential expression of 14 genes, as well as prognosis for the four subgroups of multiple myeloma based on the expression of 24 genes are established. A 15-gene model that classifies myeloma into 7 groups is also reported. Gene expression profiling also allows placing multiple myeloma into a developmental schema parallel to that of normal plasma cell differentiation. Development of a gene expression- or developmental stage-based classification system for multiple myeloma would lead to rational design of more accurate and sensitive diagnostics, prognostics and tumor-specific therapies for multiple myeloma.

    摘要翻译： 基因表达分析显示与各种临床特征有显着相关性的多个骨髓瘤的四个不同亚组。 基于14个基因的差异表达的多发性骨髓瘤的诊断（可能是未确定的意义的单克隆丙种球蛋白病），以及基于24个基因的表达的多发性骨髓瘤的四个亚组的预后。 还报道了将骨髓瘤分为7组的15基因模型。 基因表达谱也允许将多发性骨髓瘤放置在与正常浆细胞分化平行的发育模式中。 开发基因表达或基于发育阶段的多发性骨髓瘤分类系统将导致对多发性骨髓瘤的更准确和敏感的诊断，预后和肿瘤特异性治疗的合理设计。

    Use of gene expression profiling to predict survival in cancer patient
    8.
    发明授权
    Use of gene expression profiling to predict survival in cancer patient 有权
    使用基因表达谱来预测癌症患者的存活

    公开(公告)号：US07741035B2

    公开(公告)日：2010-06-22

    申请号：US11147829

    申请日：2005-06-08

    申请人： John D. Shaughnessy ,  Bart Barlogie ,  Fenghuang Zhan

    发明人： John D. Shaughnessy ,  Bart Barlogie ,  Fenghuang Zhan

    IPC分类号： C12Q1/68 ,  G01N33/48

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/178

    摘要： Gene expression profiling in multiple myeloma patients identifies genes that distinguish between patients with subsequent early death or long survival after treatment. Poor survival is linked to over-expression of genes such as ASPM, OPN3 and CKS1B which are located in chromosome 1q. Given the frequent amplification of 1q in many cancers, it is possible that these genes can be used as powerful prognostic markers and therapeutic targets for multiple myeloma and other cancer.

    摘要翻译： 在多发性骨髓瘤患者中进行基因表达谱分析鉴定了随后早期死亡或治疗后长期存活的患者之间区分的基因。 差的存活与位于染色体1q的基因如ASPM，OPN3和CKS1B的过表达有关。 鉴于许多癌症中1q的频繁扩增，这些基因可能被用作多种骨髓瘤和其他癌症的强大的预后标志物和治疗靶点。

    Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
    9.
    发明申请
    Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling 有权
    基于基因表达谱的多发性骨髓瘤的潜在治疗靶点的诊断，预后和鉴定

    公开(公告)号：US20100144673A1

    公开(公告)日：2010-06-10

    申请号：US12587383

    申请日：2009-10-06

    申请人： John D. Shaughnessy, JR. ,  Bart Barlogie ,  Fenghuang Zhan

    发明人： John D. Shaughnessy, JR. ,  Bart Barlogie ,  Fenghuang Zhan

    IPC分类号： A61K31/69 ,  C40B20/00 ,  C12Q1/68

    CPC分类号： C12Q1/6883 ,  C12Q1/6841 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  G06F19/18 ,  G06F19/20 ,  G06F19/24

    摘要： Gene expression profiling is a powerful tool that has varied utility. It enables classification of multiple myeloma into subtypes and identifying genes directly involved in disease pathogensis and clinical manifestation. The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myleoma. It is further contemplated that therapeutic strategies that directly target CKS1B or related pathways may represent novel, and more specific means of treating high risk myeloma and may prevent its secondary evolution.

    摘要翻译： 基因表达谱是一种功能多样的强大工具。 它可以将多发性骨髓瘤分类为亚型，并鉴定直接参与疾病病理和临床表现的基因。 本发明在大量均匀治疗的骨髓瘤患者群中使用基因表达谱来鉴定与预后不良相关的基因。 它还表明CKS1B基因的过表达，主要是由于通过荧光原位杂交确定的基因扩增，以在多种myleoma中预后不良。 进一步预期，直接靶向CKS1B或相关途径的治疗策略可以代表治疗高风险骨髓瘤的新颖和更具体的手段，并且可以防止其二次进化。

    Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
    10.
    发明授权
    Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss 失效
    基因表达谱基于DKK1的鉴定作为控制骨丢失的潜在治疗靶点

    公开(公告)号：US07371736B2

    公开(公告)日：2008-05-13

    申请号：US10931780

    申请日：2004-09-01

    申请人： John D. Shaughnessy ,  Bart Barlogie ,  Fenghuang Zhan

    发明人： John D. Shaughnessy ,  Bart Barlogie ,  Fenghuang Zhan

    IPC分类号： A61K39/00 ,  C12Q1/68 ,  A01N43/04 ,  A01N57/00

    CPC分类号： C12Q1/6886 ,  C12Q1/6837 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  Y02A90/26

    摘要： Gene expression profiling reveals four distinct subgroups of multiple myeloma that have significant correlation with various clinical characteristics. Diagnosis for multiple myeloma (and possibly monoclonal gammopathy of undetermined significance) based on differential expression of 14 genes, as well as prognosis for the four subgroups of multiple myeloma based on the expression of 24 genes are established. A 15-gene model that classifies myeloma into 7 groups is also reported. Gene expression profiling also allows placing multiple myeloma into a developmental schema parallel to that of normal plasma cell differentiation. Development of a gene expression- or developmental stage-based classification system for multiple myeloma would lead to rational design of more accurate and sensitive diagnostics, prognostics and tumor-specific therapies for multiple myeloma.

    摘要翻译： 基因表达分析显示与各种临床特征有显着相关性的多个骨髓瘤的四个不同亚组。 基于14个基因的差异表达的多发性骨髓瘤的诊断（可能是未确定的意义的单克隆丙种球蛋白病），以及基于24个基因的表达的多发性骨髓瘤的四个亚组的预后。 还报道了将骨髓瘤分为7组的15基因模型。 基因表达谱也允许将多发性骨髓瘤放置在与正常浆细胞分化平行的发育模式中。 开发基因表达或基于发育阶段的多发性骨髓瘤分类系统将导致对多发性骨髓瘤的更准确和敏感的诊断，预后和肿瘤特异性治疗的合理设计。